HONG KONG, 20 December 2022 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of treatments that address significant unmet medical needs, is pleased to announce that the Company has received recognition from the industry and investors, and won the “Best Small and Mid-Cap Company” award at the “Embracing 2023:  the Seventh Golden Hong Kong Stocks Annual Awards Ceremony”, jointly held by Zhitong Finance, China Galaxy Securities and RoyalFlush Information.

This year's award-winners were selected after two months of rigorous assessment. Twenty-four awards were presented in total, including 17 awards for companies, and 7 awards for individuals and teams. The selection adheres to the principle of fairness and openness. The judging committee is composed of multiple Chinese and Hong Kong securities companies, economists, and professional investors. The committee reviewed and graded the candidates based on their business growth, industry ranking, corporate governance, business model, market influence and capital market performance over the past year. Public voting was also taken into account.

The selection attracted over 1,000 Hong Kong and US listed companies to participate. In addition to traditional industries such as energy, finance, automobiles and industrial manufacturing, it also covers emerging industries which lead the Chinese economy in transition including communications, chip manufacturing, internet and medical care.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented: "We are honoured to receive the award for the ‘Best Small and Mid-Cap Company’ and we would like to express our gratitude towards the organizers and judges for their recognition of Zhaoke Ophthalmology again. This year, Zhaoke Ophthalmology has not only made important clinical progress in the development of our pipeline drugs, but also achieved a huge breakthrough in commercialization. In 2023, we will continue to dedicate our efforts in two major aspects - R&D and commercialization, with an aim to provide treatment solutions for patients with eye diseases, improve China’s public visual health, as well as continue to enhance our Company's recognition in the capital market."